Allarta’s Proprietary Platform
Designed to overcome immune rejection, prevent cell escape and safely deliver allogeneic cell therapies.
Allarta’s lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.
Diabetes DONOR Islet Transplants
Diabetes BETA Cell Therapy as SoC
Rare Blood Disorders
Oncology Solid Tumors
Cardiac and Inflammatory Indications